View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 30, 2021updated 11 Jul 2022 3:09pm

Scancell gets South Africa’s approval for Covid-19 vaccines trial

Part one of the trial will be conducted in South Africa while Part two will expand to the UK sites.

UK-based drug company Scancell has received approval from the South African Health Products Regulatory Authority (SAHPRA) to conduct a Phase I clinical trial of its Covid-19 vaccine candidates.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Referred to as COVIDITY-001, the trial is part of the COVIDITY programme designed to assess the company’s SCOV1 and SCOV2 vaccines.

Scancell is carrying out COVIDITY in partnership with researchers from the Centre for Research on Global Virus Infections and the Biodiscovery Institute at the University of Nottingham and Nottingham Trent University.

SCOV1 targets the original SARS-CoV-2 strain while SCOV2 acts on the variants of the virus.

Both vaccines are developed using an alteration of Scancell ‘s ImmunoBody DNA vaccine technology and stimulate T-cell immune responses against the N and S antigens of SARS-CoV-2.

They target the S antigen’s receptor-binding domain (RBD) to induce cross-reactive virus-neutralising antibodies (VNAbs) against multiple variants of concern such as the new Delta variant.

Scancell CEO professor Lindy Durrant said: “Our approach of targeting the conserved N protein in addition to generating potent, cross-reactive VNAbs has the potential to provide a significant clinical advantage by eliciting potent T cells that can destroy cells infected with any SARSCoV-2 variants and other SARS-CoV viruses that may emerge in the future.”

The Phase I COVIDITY-001 trial is expected to commence in the second half of this year.

Part one of the trial, to be performed at the University of Cape Town Lung Institute in South Africa, will enrol vaccine-naïve, healthy adults.

Scancell noted that sites in the UK will not be involved in Part one because of the country’s vaccination programme and no unvaccinated individuals who are required for preliminary safety assessment.

This part will evaluate the safety and immunogenicity of SCOV1 and SCOV2 at various doses administered using needle-free systems via two different injection routes.

If positive safety data is obtained, the company will apply to the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) to launch an extension of the trial in the country.

The extension, Part two, will involve healthy participants who have previously taken two doses of a vaccine that has been authorised. It will monitor immune responses generated by Scancell ‘s vaccines.

Earlier this month, SAHPRA approved ImmunityBio’s Phase I/II/III trial of dual-antigen T-cell Covid-19 vaccine.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena